Morgan Stanley analyst Jeffrey Hung upgraded Neurocrine to Overweight from Equal Weight with a price target of $130, up from $120. The analyst believes Neurocrine is well positioned for share appreciation with multiple data readouts expected this year. Investors largely expect approval of Ingrezza for Huntington’s disease chorea, but there is incremental upside to the shares with potential approval by the August 20 FDA action date, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NBIX:
- Xenon Pharmaceuticals outlines key milestone opportunities for 2023
- Voyager, Neurocrine enter collaboration to advance multiple gene therapies
- Neurocrine: FDA accepts sNDA for valbenazine
- Neurocrine CAH data appears pushed back, says RBC Capital
- Neurocrine announces NBI-827104 did not meet its primary endpoint in Phase 2